Treatment of High Risk Adult Acute Lymphoblastic Leukemia

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

Vincristine

Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)

DRUG

Daunorubicin

Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22

DRUG

Prednisone

Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28

DRUG

Mitoxantrone

Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation

DRUG

Cytosine Arabinoside

ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction

DRUG

Dexamethasone

Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)

DRUG

Methotrexate (MTX)

Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT

DRUG

Cytarabine

Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal

DRUG

ASP

ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)

DRUG

Mercaptopurine

Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation

DRUG

Teniposide

Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3

DRUG

Hydrocortisone

Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal

Trial Locations (38)

Unknown

Hospital Juan Canalejo, A Coruña

Hospital General, Alicante

Hospital Germans Trias i Pujol, Badalona

Clínica Teknon, Barcelona

Hospital Clínic i Provincial, Barcelona

Hospital de Sant Pau, Barcelona

Hospital Duran y Reynals, Barcelona

Hospital Vall d'Hebrón, Barcelona

Hospital Puerta del Mar, Cadiz

Hospital General, Castellon

Hospital San Pedro de Alcántara, Cáceres

Hospital Josep Trueta, Girona

Hospital Universitario, Guadalajara

Hospital Xeral, Lugo

Hospital 12 de Octubre, Madrid

Hospital Clínico Universitario, Madrid

Hospital de Fuenlabrada, Madrid

Hospital Ramón y Cajal, Madrid

Hospital Carlos Haya, Málaga

Hospital Virgen de la Victoria, Málaga

Hospital Morales Messeguer, Murcia

Hospital Central de Asturias, Oviedo

Hospital Son Llàtzer, Palma de Mallorca

Clínica Universitaria de Navarra, Pamplona

Hospital Parc Taulí, Sabadell

Hospital Clínico Universitario, Salamanca

Hospital Marqués de Valdecilla, Santander

Hospital Xeral, Santiago

Hospital Virgen del Rocio, Seville

Hospital Joan XXIII, Tarragona

Hospital Mútua de Terrassa, Terrassa

Hospital Clínico Universitario, Valencia

Hospital Dr Pesset, Valencia

Hospital General, Valencia

Hospital La Fe, Valencia

Hospital Clínico, Valladolid

Hospital Virgen de la Concha, Zamora

Hospital Lozano Blesa, Zaragoza

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT00853008 - Treatment of High Risk Adult Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter